GlassScriptPhysician profile
Gladys Onojobi
NPI 1912944901
$5,594.21
in general payments reported to CMS, 2019-2025
41 companies · $926 in 2025
The $926 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,115 · 2020: $466 · 2021: $340 · 2022: $478 · 2023: $625 · 2024: $1,644 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,079 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,079.22 |
| Education | $116.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,243.42 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $637.15 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $415.17 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Rigel Pharmaceuticals, INC. | $337.42 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Glaxosmithkline, LLC. | $290.21 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Daiichi Sankyo INC. | $253.05 | 2023-2024 | Enhertu, Vanflyta |
| Genzyme Corporation | $231.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $224.46 | 2019-2024 | Calquence |
| Novartis Pharmaceuticals Corporation | $173.50 | 2019-2025 | |
| Janssen Biotech, INC. | $146.60 | 2019-2025 | Rybrevant, Akeega, Balversa |
| Aveo Pharmaceuticals, INC. | $136.82 | 2022-2024 | |
| Array Biopharma INC | $109.26 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Celgene Corporation | $108.39 | 2021-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $107.35 | 2020-2025 | Alunbrig, Iclusig, Ninlaro |
| Astellas Pharma US INC | $104.69 | 2019-2025 | Xtandi |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $102.18 | 2024-2025 | Onivyde, Somatuline Depot, Tazverik |
| Exelixis INC. | $92.02 | 2019-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $82.67 | 2020-2023 | Epkinly |
| Foundation Medicine, INC. | $80.83 | 2022 | |
| Genentech USA, INC. | $74.35 | 2019-2025 | Tecentriq, Alecensa, Tecentriq Hybreza |
| Pharmaessentia USA Corporation | $66.34 | 2024-2025 | Besremi |
| Abbvie INC. | $57.72 | 2020-2024 | |
| Eisai INC. | $57.14 | 2020-2023 | |
| Boston Scientific Corporation | $52.28 | 2019-2023 | Watchman Access System |
| Seagen INC. | $50.18 | 2019-2023 | Padcev |
| Servier Pharmaceuticals LLC | $48.61 | 2024-2025 | |
| Taiho Oncology, INC. | $46.95 | 2023-2024 | |
| Tactile Systems Technology INC | $33.27 | 2025 | Nimbl, Flexitouch Plus |
| Pharmacosmos Therapeutics INC. | $27.01 | 2024 | Monoferric |
| Lilly USA, LLC | $24.41 | 2025 | Jaypirca, Verzenio |
| Incyte Corporation | $21.76 | 2025 | Monjuvi, Zynyz |
| Emd Serono, INC. | $21.53 | 2025 | |
| Stemline Therapeutics INC. | $20.39 | 2024 | Orserdu |
| Karyopharm Therapeutics INC. | $18.74 | 2024 | Xpovio |
| Ferring Pharmaceuticals INC. | $17.76 | 2019 | |
| Springworks Therapeutics, INC. | $14.95 | 2025 | Ogsiveo |
| Blueprint Medicines Corporation | $13.48 | 2022 | |
| Sobi, INC | $13.38 | 2024 | |
| Novocure INC. | $12.93 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.63 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gladys Onojobi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.